Latanoprost rescues retinal neuro-glial cells from apoptosis by inhibiting caspase-3, which is mediated by p44/p42 mitogen-activated protein kinase

Experimental Eye Research

Volumn 83, Issue 5, 2006, Pages 1108-1117

  Nakanishi, Yoriko ^a   Nakamura, Makoto ^a   Mukuno, Hirokazu ^a   Kanamori, Akiyasu ^a   Seigel, Gail M ^b   Negi, Akira ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

apoptosis; diabetic retinopathy; latanoprost; mitogen activated protein kinase; retinal neurodegeneration

Indexed keywords

BALANCED SALT SOLUTION; CASPASE 3; LATANOPROST; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DOSE RESPONSE; ENZYME INHIBITION; IMMUNOCOMPETENT CELL; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETINA BIPOLAR GANGLION CELL; RETINA NERVE CELL; RETINA NEUROEPITHELIAL LAYER; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CASPASE 3; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; IMMUNOHISTOCHEMISTRY; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEUROGLIA; NEUROPROTECTIVE AGENTS; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; RATS; RATS, SPRAGUE-DAWLEY; RETINA; RETINAL GANGLION CELLS; STEM CELLS;

EID: 33748698035     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2006.05.018     Document Type: Article

References (74)

1. Abu-El-Asrar A.M., Dralands L., Missotten L., Al-Jadaan I.A., and Geboes K. Expression of apoptosis markers in the retinas of human subjects with diabetes. Invest. Ophthalmol. Vis. Sci. 45 (2004) 2760-2766
2. Agardh E., Bruun A., and Agardh C.D. Retinal glial cell immunoreactivity and neuronal cell changes in rats with STZ-induced diabetes. Curr. Eye Res. 23 (2001) 276-284
3. Aihara M., Lindsey J.D., and Weinreb R.N. Enhanced FGF-2 movement through human sclera after exposure to latanoprost. Invest. Ophthalmol. Vis. Sci. 42 (2001) 2554-2559
4. Ambati J., Chalam K.V., Chawla D.K., D'Angio C.T., Guillet E.G., Rose S.J., Vanderlinde R.E., and Ambati B.K. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch. Ophthalmol. 115 (1997) 1161-1166
5. 2α, latanoprost and carbachol on phosphoinositide turnover, MAP kinases, myosin light chain phosphorylation and contraction and functional existence and expression of FP receptors in bovine iris sphincter. Exp. Eye Res. 78 (2004) 285-296
6. Aviles-Trigueros M., Mayor-Torroglosa S., Garcia-Aviles A., Lafuente M.P., Rodriduez M.E., Miralles de Imperial J., Villegas-Perez M.P., and Videl-Sanz M. Transient ischemia of the retina results in massive degeneration of the retinotectal projection: long-term neuroprotection with brimonidine. Exp. Neurol. 184 (2003) 767-777
7. Barber A.J. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 283-290
8. Barber A.J., Lieth E., Khin S.A., Antonetti D.A., Buchanan A.G., and Gardner T.W. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J. Clin. Invest. 102 (1998) 783-791
9. Barber A.J., Antonetti D.A., and Gardner T.W. Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. Invest. Ophthalmol. Vis. Sci. 41 (2000) 3561-3568
10. Barber A.J., Nakamura M., Wolpert E.B., Reiter C.E., Seigel G.M., Antonetti D.A., and Gardner T.W. Insulin rescues retinal neurons from apoptosis by a phosphatidylinositol 3-kinase/Akt-mediated mechanism that reduces the activation of caspase-3. J. Biol. Chem. 276 (2001) 32814-32821
11. Bito N.A., and Baroody R.A. The ocular pharmacokinetics of eicosanoids and their derivatives. 1. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF2 alpha, PGF2 alpha-1-methyl ester, and PGF2 alpha-1-isopropyl ester. Exp. Eye Res. 44 (1987) 217-226
12. Bloodworth Jr. J.M. Diabetic retinopathy. Diabetes 11 (1962) 1-22
13. Bresnick G.H. Diabetic retinopathy viewed as a neurosensory disorder. Arch. Ophthalmol. 104 (1986) 989-990
14. Cazevieille C., Muller A., Meynier F., Dutrait N., and Bonne C. Protection by prostaglandins from glutamate toxicity in cortical neurons. Neurochem. Int. 24 (1994) 395-398
15. Chen W., Andom T., Bhattacherjee P., and Paterson C. Intracellular calcium mobilization following prostaglandin receptor activation in human ciliary muscle cells. Curr. Eye Res. 16 (1997) 847-853
16. Chen W., Jump D.B., Grant M.B., Esselman W.J., and Busik J.V. Dyslipidemia, but not hyperglycemia, induces inflammatory adhesion molecules in human retinal vascular endothelial cells. Invest. Ophthalmol. Vis. Sci. 44 (2003) 5016-5022
17. Cobb M.H. MAP kinase pathways. Prog. Biophys. Mol. Biol. 71 (1999) 479-500
18. Davis T.L., and Sharif N.A. Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology. J. Ocul. Pharmacol. Ther. 15 (1999) 323-336
19. Della Sala S., Bertoni G., Somazzi L., Stubbe F., and Wilkins A.J. Impaired contrast sensitivity in diabetic patients with and without retinopathy: a new technique for rapid assessment. Br. J. Ophthalmol. 69 (1985) 136-142
20. Dosso A.A., Yenice-Ustun F., Sommerhalder J., Golay A., Morel Y., and Leuenberger P.M. Contrast sensitivity in obese dyslipidemic patients with insulin resistance. Arch. Ophthalmol. 116 (1998) 1316-1320
21. Drago F., Valzelli S., Emmi I., Marino A., Scalia C.C., and Marino V. Latanoprost exerts neuroprotective activity in vitro and in vivo. Exp. Eye Res. 72 (2001) 479-486
22. Du Y., Sarthy V.P., and Kern T.S. Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287 (2004) 735-741
23. Fong D.S., Barton F.B., and Bresnick G.H. Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. Am. J. Ophthalmol. 128 (1999) 612-617
24. Gardner T.W., Antonetti D.A., Barber A.J., LaNoue K.F., and Levison S.W. Diabetic retinopathy: more than meets the eye. Surv. Ophthalmol. 47 (2002) S253-S262
25. Griffin B.W., Magnino P.E., Pang I.H., and Sharif N.A. Pharmacological characterization of an FP prostaglandin receptor on rat vascular smooth muscle cells (A7r5) coupled to phosphoinositide turnover and intracellular calcium mobilization. J. Pharmacol. Exp. Ther. 286 (1998) 411-418
26. Hammes H.P., Federoff H.J., and Brownlee M. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol. Med. 1 (1995) 527-534
27. Hotehama Y., and Mishima H.K. Clinical efficacy of PhXA34 and PhXA41, two novel prostaglandin F2 alpha-isopropyl ester analogues for glaucoma treatment. Jpn. J. Ophthalmol. 37 (1993) 259-269
28. 2α stimulates tyrosine phosphorylation of phospholipase C-γ1. Biochem. Biophys. Res. Commun. 297 (2002) 1102-1107
29. Ishii K., Tomidokoro A., Nagahara M., Tamaki Y., Kanno M., Fukaya Y., and Araie M. Effects of topical latanoprost optic nerve head circulation in rabbits, monkeys, and humans. Invest. Ophthalmol. Vis. Sci. 42 (2001) 2957-2963
30. Joussen A.M., Poulaki V., Mitsiades N., Kirchhof B., Koizumi K., Döhmen S., and Adamis A.P. Non-steroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-α suppression. FASEB J. 16 (2002) 438-440
31. Joussen A.M., Poulaki V., Le M.L., Koizumi K., Esser C., Janicki H., Schraemeyer U., Kociok N., Fauser S., Kirchhof B., Kern T.S., and Adamis A.P. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 18 (2004) 1450-1452
32. Juen S., and Kieselbach G.F. Electrophysiological changes in juvenile diabetics without retinopathy. Arch. Ophthalmol. 108 (1990) 372-375
33. Kanamori A., Nakamura M., Mukuno H., Maeda H., and Negi A. Diabetes has an additive effect on neural apoptosis in rat retina with chronically elevated intraocular pressure. Curr. Eye Res. 28 (2004) 47-54
34. Kanamori A., Nakamura M., Nakanishi Y., Nagai A., Mukuno H., Yamada Y., and Negi A. Akt is activated via insulin/IGF-1 receptor in rat retina with episcleral vein cauterization. Brain Res. 1022 (2004) 195-204
35. 2+ mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors. J. Pharmacol. Exp. Ther. 304 (2003) 238-245
36. Kim T.W., Lindsey J.D., Aihara M., Anthony T.L., and Weinreb R.N. Intraocular distribution of 70-kDa dextran after subconjunctival injection in mice. Invest. Ophthalmol. Vis. Sci. 43 (2002) 1809-1816
37. 2α receptors coupled to phopholipase C. Biochem. Biophys. Res. Commun. 178 (1991) 946-952
38. Kowluru R.A., Engreman R.L., Case G.L., and Kern T.S. Retinal glutamate in diabetes and effect of antioxidants. Neurochem. Int. 38 (2001) 385-390
39. Levin L.A. Retinal ganglion cells and neuroprotection for glaucoma. Surv. Ophthalmol. 48 (2003) S21-S24
40. Lieth E., Barber A.J., Xu B., Dice C., Ratz M.J., Tanase D., and Strother J.M. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Diabetes 47 (1998) 815-820
41. Lieth E., LaNoue K.F., Antonetti D.A., and Ratz M. Diabetes reduces glutamate oxidation and glutamine synthesis in the retina. Exp. Eye Res. 70 (2000) 723-730
42. Manabe S., and Lipton S.A. Divergent NMDA signals leading to proapoptotic and antiapoptotic pathways in the rat retina. Invest. Ophthalmol. Vis. Sci. 44 (2003) 385-392
43. Manchanda R., Kim J.M., and Tsang B.K. Role of prostaglandins in the suppression of apoptosis in hen granulosa cells by transforming growth factor alpha. Reproduction 122 (2001) 91-101
44. Martin P.M., Roon P., Van Ells T.K., Ganapathy V., and Smith S.B. Death of retinal neurons in streptozotocin-induced diabetic mice. Invest. Ophthalmol. Vis. Sci. 45 (2004) 3330-3336
45. Mizuno K., Koide T., Saito N., Fujii M., Nagahara M., Tomidokoro A., Tamaki Y., and Araie M. Topical nipradilol: effects on optic nerve head circulation in humans and periocular distribution in monkeys. Invest. Ophthalmol. Vis. Sci. 43 (2002) 3243-3250
46. Mizutani M., Gerhardinger C., and Lorenzi M. Mu{combining double acute accent}ller cell changes in human diabetic retinopathy. Diabetes 47 (1998) 44-449
47. Mohr S., Xi X., Tang J., and Kern T.S. Caspase activation in retinas of diabetic and galactosemic mice and diabetic patients. Diabetes 51 (2002) 1172-1179
48. Morissette M.R., Howes A.L., Zhang T., and Heller Brown J. Upregulation of GLUT1 expression is necessary for hypertrophy and survival of neonatal rat cardiomyocytes. J. Mol. Cell. Cardiol. 35 (2003) 1217-1227
49. Mukuno H., Nakamura M., Kanamori A., Nagai A., Negi A., and Seigel G.M. Unoprostone isopropyl rescues retinal progenitor cells from apoptosis in vitro. Curr. Eye Res. 29 (2004) 457-464
50. Nakamura M., Barber A.J., Antonetti D.A., LaNoue K.F., Robinson K.A., Buse M.G., and Gardner T.W. Excessive hexosamines block the neuroprotective effect of insulin and induce apoptosis in retinal neurons. J. Biol. Chem. 276 (2001) 43748-43755
51. Nakamura M., Kanamori A., and Negi A. Diabetes mellitus as a risk factor for glaucomatous optic neuropathy. Ophthalmologica 219 (2005) 1-10
52. Narayanan R., Mungcal J.K., Kenny M.C., Seigel G.M., and Kuppermann B.D. Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 47 (2006) 722-728
53. Nishimura K., Tsumagari H., Setoyama T., Morioka A., Lu S., Jisaka M., Nagaya T., and Yokota K. Prostaglandin F (2alpha) is protective for apoptosis stimulated synergistically with 12-O-tetradecanoyl phorbol-beta-acetate and nordihydroguaiaretic acid in Madin-Darby canine kidney cells. Biochim. Biophys. Acta. 1682 (2004) 102-111
54. Ocklind A., Lake S., Wentzel P., Nister M., and Stjernschantz J. Localization of the prostaglandin F2 alpha receptor messenger RNA and protein in the cynomolgus monkey eye. Invest. Ophthalmol. Vis. Sci. 37 (1996) 716-726
55. 2 alpha receptor in rat tissues. Prostaglandins Leukot. Essent. Fatty Acids 57 (1997) 527-532
56. Podesta F., Romeo G., Liu W.H., Krajewski S., Reed J.C., Gerhardinger C., and Lorenzi M. Bax is increased in the retina of diabetic subjects and is associated with pericyte apoptosis in vivo and in vitro. Am. J. Pathol. 156 (2000) 1026-1032
57. Rungger-Brändle E., Dosso A.A., and Leuenberger P.M. Glial reactivity, an early feature of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 41 (2000) 1971-1980
58. Seigel G.M. Establishment of an E1A-immortalized retinal cell culture. In Vitro Cell Dev. Biol. Anim. 32 (1996) 66-68
59. Seigel G.M., and Liu L. Inducible apoptosis-promoting activity in retinal cell-conditioned medium. Mol. Vis. 3 (1997) 14
60. Seigel G.M., Mutchler A.L., and Imperato E.L. Expression of glial markers in a retinal precursor cell line. Mol. Vis. 2 (1996) 2
61. Seigel G.M., Chiu L., and Paxhia A. Inhibition of neuroretinal cell death by insulin-like growth factor-1 and its analogs. Mol. Vis. 6 (2000) 157-163
62. Seigel G.M., Sun W., Wang J., Hershberger D.H., Campbell L.M., and Salvi R.J. Neuronal gene expression and function in the growth-stimulated R28 retinal precursor cell line. Curr. Eye Res. 28 (2004) 257-269
63. Sharif N.A., Kelly C.R., and Crider J.Y. Agonist activity of bimatoprost, travoprost, latanoprost, Unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J. Ocul. Pharmacol. Ther. 18 (2002) 313-324
64. Sharif N.A., Kelly C.R., Crider J.Y., Williams G.W., and Xu S.X. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J. Ocul. Pharmacol. Ther. 19 (2003) 501-515
65. Simonsen S.E. The value of the oscillatory potential in selecting juvenile diabetics at risk of developing proliferative retinopathy. Acta Ophthalmol. (Copenh.) 58 (1980) 865-878
66. Stjernschantz J., Selen G., Ocklind A., and Resul B. Effects of latanoprost and related prostaglandin analogues. In: Alm A., and Weinreb R.N. (Eds). Uveoscleral Outflow. Biology and Clinical Aspects (1998), Mosby-Wolfe Medical Communications, London 57-72
67. Sun W., Seigel G.M., and Salvi R.J. Retinal precursor cells express functional ionotropic glutamate and GABA receptors. Neuroreport 13 (2002) 2421-2424
68. Tezel G., and Wax M.B. The mechanisms of hsp27 antibody-mediated apoptosis in retinal neuronal cells. J. Neurosci. 20 (2000) 3552-3562
69. Toris C.B., Camras C.B., and Yablonski M.E. Effects of PhX41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 100 (1993) 1297-1304
70. Trier K., and Ribel-Madsen S.M. Latanoprost eye drops increase concentration of glycosaminoglycans in posterior rabbit sclera. J. Ocul. Pham. Ther. 20 (2004) 185-188
71. Van der Valk R., Webers C.A., Schouten J.S., Zeegers M.P., Hendrikse F., and Prins M.H. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 112 (2005) 1177-1185
72. Warwar R.E., Bullock J.D., and Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 105 (1998) 263-268
73. Wolter J.R. Diabetic retinopathy. Am. J. Ophthalmol. 51 (1961) 1123-1141
74. Zeng X.X., Ng Y.K., and Ling E.A. Neuronal and microglial response in the retina of strepozotocin-induced diabetic rats. Vis. Neurosci. 17 (2000) 463-471